To Study the Pathophysiological Features of Multiple Sclerosis
Conditions: Multiple Sclerosis; Neurofilament Light Chain; Glial Fibrillary Acidic Protein Intervention: Drug: 18F-PM-PBB3 Sponsor: Chang Gung Memorial Hospital Not yet recruiting
ConclusionsNatalizumab is highly effective as measured by the NEDA long-term remission parameter.ResumenIntroducciónLa efectividad y seguridad de natalizumab en pacientes con esclerosis múltiple remitente recurrente (EMRR) se demostró en ensayos clínicos. Sin embargo, por las limitaciones de estos, es importante saber cómo se comporta en condiciones de práctica clínica a largo plazo.ObjetivoConocer la eficacia a largo plazo de natalizumab en pacientes con EMRR mediante la evaluación anual del NEDA (no evidence of disease activity), que incluye número de brotes,...
CONCLUSIONS: The results indicate that, although persons with disabilities can exhibit a wide functional range, they remain at risk of PUs and should be evaluated for proper preventive measures, including support surfaces and wheelchair cushions. PMID: 32058440 [PubMed - in process]
Authors: Gajofatto A, Turatti M Abstract Siponimod fumarate (BAF-312) is a synthetic sphingosine 1- phosphate (S1P) receptor modulator, which exerts immunomodulating effects mediated by B- and T-cell sequestration in secondary lymphoid organs. S1P receptor modulators have consistently shown a significant benefit on relapse rate and other measures of disease activity in patients with relapsing multiple sclerosis (MS), compared with both placebo and active comparator. However, most clinical trials of S1P receptor modulators--as well as other therapies for MS--lack evidence of a significant benefit on disability progr...
Publication date: Available online 15 February 2020Source: Multiple Sclerosis and Related DisordersAuthor(s): Frédéric London, Blandine Cambron, Sophie Jacobs, Paul Delrée, Thierry Gustin
Conclusion: SES and race may influence affective symptoms reported by individuals with MS. The reasons for the correlation are likely multifactorial. Longitudinal studies should strive to identify factors associated with risk of affective symptoms in MS that may be modifiable.
Publication date: Available online 13 February 2020Source: Multiple Sclerosis and Related DisordersAuthor(s): G. Luetic, ML MenichiniGraphical abstract
Publication date: Available online 13 February 2020Source: Autoimmunity ReviewsAuthor(s): Johann Sellner, Paulus S. RommerAbstractImmune reconstitution therapy (IRT) is an emerging concept for the treatment of multiple sclerosis (MS) that is given intermittently and can induce long-term remission of MS that is sustained in treatment-free periods. A systematic literature review was performed to identify and summarize current knowledge regarding the short- and long-term immunological consequences of different IRTs and CD20 depleting therapies on the cellular level in patients with MS. A total of 586 articles published betwee...
ConclusionsThe mechanisms of peripheral nerve system involvement in MOG ‐EM are unknown, but the present case suggests that MOG‐EM might occasionally combine with peripheral nerve system disturbance. Lumbosacral radiculitis combined with MOG‐IgG can be refractory, and serious sequela might be observed.
Conclusions: Interestingly, as shown in the CNS, a relationship between clinical, inflammatory MS features and glutamate clearance can be also assessed in platelets. Moreover, glutamate uptake activity might be an useful biomarker to characterize patients with benign prognosis.Graphical abstract
ConclusionsWe highly recommend considering JCPyV-DNA detection and NCCR re-organizations as viral biomarkers in order to accurately identify JCPyV-infected patients with a specific humoral response not yet detectable and to identify NCCR arrangements correlated with the onset of neurovirulent variants.